nodes	percent_of_prediction	percent_of_DWPC	metapath
Flecainide—CYP2C9—Bexarotene—hematologic cancer	0.0581	0.103	CbGbCtD
Flecainide—CYP2D6—Lomustine—hematologic cancer	0.0494	0.0874	CbGbCtD
Flecainide—CYP2C9—Idarubicin—hematologic cancer	0.0481	0.0852	CbGbCtD
Flecainide—CYP2D6—Idarubicin—hematologic cancer	0.044	0.0779	CbGbCtD
Flecainide—CYP2D6—Hydroxyurea—hematologic cancer	0.0374	0.0662	CbGbCtD
Flecainide—CYP2C9—Bortezomib—hematologic cancer	0.0356	0.063	CbGbCtD
Flecainide—CYP2D6—Bortezomib—hematologic cancer	0.0325	0.0576	CbGbCtD
Flecainide—CYP2C9—Thalidomide—hematologic cancer	0.031	0.0549	CbGbCtD
Flecainide—CYP2C9—Teniposide—hematologic cancer	0.0296	0.0524	CbGbCtD
Flecainide—CYP2C9—Ifosfamide—hematologic cancer	0.0273	0.0483	CbGbCtD
Flecainide—CYP2C9—Imatinib—hematologic cancer	0.0261	0.0462	CbGbCtD
Flecainide—CYP2D6—Imatinib—hematologic cancer	0.0238	0.0422	CbGbCtD
Flecainide—CYP2C9—Nilotinib—hematologic cancer	0.0237	0.0419	CbGbCtD
Flecainide—CYP2D6—Nilotinib—hematologic cancer	0.0217	0.0384	CbGbCtD
Flecainide—CYP2D6—Vinorelbine—hematologic cancer	0.0215	0.038	CbGbCtD
Flecainide—CYP2C9—Cisplatin—hematologic cancer	0.0133	0.0235	CbGbCtD
Flecainide—CYP2D6—Vinblastine—hematologic cancer	0.0132	0.0234	CbGbCtD
Flecainide—CYP2C9—Dexamethasone—hematologic cancer	0.0107	0.019	CbGbCtD
Flecainide—CYP2D6—Dexamethasone—hematologic cancer	0.00981	0.0174	CbGbCtD
Flecainide—CYP2D6—Doxorubicin—hematologic cancer	0.00814	0.0144	CbGbCtD
Flecainide—Mefloquine—ABCB1—hematologic cancer	0.000709	1	CrCbGaD
Flecainide—SCN5A—Axon guidance—ABL1—hematologic cancer	6.69e-05	0.00174	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—HES1—hematologic cancer	6.66e-05	0.00173	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—NCOR1—hematologic cancer	6.62e-05	0.00172	CbGpPWpGaD
Flecainide—CYP2D6—Biological oxidations—GSTO1—hematologic cancer	6.58e-05	0.00171	CbGpPWpGaD
Flecainide—SCN4A—Axon guidance—CREB1—hematologic cancer	6.56e-05	0.00171	CbGpPWpGaD
Flecainide—CYP2C9—Biological oxidations—GSTO1—hematologic cancer	6.53e-05	0.0017	CbGpPWpGaD
Flecainide—CYP2D6—Metapathway biotransformation—GSTO1—hematologic cancer	6.49e-05	0.00169	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—FOXO1—hematologic cancer	6.45e-05	0.00168	CbGpPWpGaD
Flecainide—CYP2C9—Metapathway biotransformation—GSTO1—hematologic cancer	6.44e-05	0.00167	CbGpPWpGaD
Flecainide—SCN4A—Axon guidance—IL6R—hematologic cancer	6.4e-05	0.00166	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—JAK1—hematologic cancer	6.32e-05	0.00164	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—PTPRC—hematologic cancer	6.3e-05	0.00164	CbGpPWpGaD
Flecainide—CYP2D6—Biological oxidations—UGT1A1—hematologic cancer	6.19e-05	0.00161	CbGpPWpGaD
Flecainide—CYP2C9—Biological oxidations—UGT1A1—hematologic cancer	6.14e-05	0.0016	CbGpPWpGaD
Flecainide—CYP2D6—Metapathway biotransformation—UGT1A1—hematologic cancer	6.11e-05	0.00159	CbGpPWpGaD
Flecainide—SCN4A—Axon guidance—MAP2K1—hematologic cancer	6.1e-05	0.00159	CbGpPWpGaD
Flecainide—CYP2C9—Metapathway biotransformation—UGT1A1—hematologic cancer	6.05e-05	0.00157	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—PHYH—hematologic cancer	6.04e-05	0.00157	CbGpPWpGaD
Flecainide—SCN5A—Axon guidance—JAK1—hematologic cancer	6e-05	0.00156	CbGpPWpGaD
Flecainide—SCN5A—SIDS Susceptibility Pathways—IL1B—hematologic cancer	5.92e-05	0.00154	CbGpPWpGaD
Flecainide—SCN5A—SIDS Susceptibility Pathways—CASP3—hematologic cancer	5.91e-05	0.00154	CbGpPWpGaD
Flecainide—SCN5A—SIDS Susceptibility Pathways—JUN—hematologic cancer	5.74e-05	0.00149	CbGpPWpGaD
Flecainide—SCN4A—Axon guidance—JAK2—hematologic cancer	5.56e-05	0.00145	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—SMPD3—hematologic cancer	5.52e-05	0.00143	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—HSP90AA1—hematologic cancer	5.51e-05	0.00143	CbGpPWpGaD
Flecainide—CYP2D6—Biological oxidations—MTR—hematologic cancer	5.37e-05	0.0014	CbGpPWpGaD
Flecainide—CYP2C9—Biological oxidations—MTR—hematologic cancer	5.32e-05	0.00138	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—MAPK14—hematologic cancer	5.3e-05	0.00138	CbGpPWpGaD
Flecainide—SCN5A—SIDS Susceptibility Pathways—EP300—hematologic cancer	5.29e-05	0.00138	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—CDK4—hematologic cancer	5.22e-05	0.00136	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—MET—hematologic cancer	5.22e-05	0.00136	CbGpPWpGaD
Flecainide—CYP2D6—Biological oxidations—GSTT1—hematologic cancer	5.11e-05	0.00133	CbGpPWpGaD
Flecainide—CYP2C9—Biological oxidations—GSTT1—hematologic cancer	5.06e-05	0.00132	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—NOTCH1—hematologic cancer	5.03e-05	0.00131	CbGpPWpGaD
Flecainide—SCN5A—SIDS Susceptibility Pathways—VEGFA—hematologic cancer	5.01e-05	0.0013	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—GRB2—hematologic cancer	4.97e-05	0.00129	CbGpPWpGaD
Flecainide—SCN5A—Axon guidance—MET—hematologic cancer	4.96e-05	0.00129	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—PTPN11—hematologic cancer	4.83e-05	0.00126	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—ABL1—hematologic cancer	4.78e-05	0.00124	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—CREB1—hematologic cancer	4.68e-05	0.00122	CbGpPWpGaD
Flecainide—Gastrointestinal disorder—Betamethasone—hematologic cancer	4.61e-05	0.000116	CcSEcCtD
Flecainide—Fatigue—Betamethasone—hematologic cancer	4.6e-05	0.000116	CcSEcCtD
Flecainide—Fatigue—Dexamethasone—hematologic cancer	4.6e-05	0.000116	CcSEcCtD
Flecainide—Pruritus—Etoposide—hematologic cancer	4.59e-05	0.000116	CcSEcCtD
Flecainide—SCN5A—Axon guidance—PTPN11—hematologic cancer	4.59e-05	0.00119	CbGpPWpGaD
Flecainide—Shock—Prednisone—hematologic cancer	4.58e-05	0.000116	CcSEcCtD
Flecainide—Pain—Betamethasone—hematologic cancer	4.57e-05	0.000115	CcSEcCtD
Flecainide—Pain—Dexamethasone—hematologic cancer	4.57e-05	0.000115	CcSEcCtD
Flecainide—SCN4A—Developmental Biology—IL6R—hematologic cancer	4.57e-05	0.00119	CbGpPWpGaD
Flecainide—Visual impairment—Doxorubicin—hematologic cancer	4.57e-05	0.000115	CcSEcCtD
Flecainide—Nervous system disorder—Prednisone—hematologic cancer	4.56e-05	0.000115	CcSEcCtD
Flecainide—SCN4A—Developmental Biology—CREBBP—hematologic cancer	4.56e-05	0.00119	CbGpPWpGaD
Flecainide—Tachycardia—Prednisone—hematologic cancer	4.54e-05	0.000115	CcSEcCtD
Flecainide—Alopecia—Epirubicin—hematologic cancer	4.52e-05	0.000114	CcSEcCtD
Flecainide—Skin disorder—Prednisone—hematologic cancer	4.52e-05	0.000114	CcSEcCtD
Flecainide—SCN5A—Developmental Biology—HES1—hematologic cancer	4.52e-05	0.00117	CbGpPWpGaD
Flecainide—Nausea—Gemcitabine—hematologic cancer	4.51e-05	0.000114	CcSEcCtD
Flecainide—Vomiting—Cisplatin—hematologic cancer	4.5e-05	0.000114	CcSEcCtD
Flecainide—Hyperhidrosis—Prednisone—hematologic cancer	4.5e-05	0.000114	CcSEcCtD
Flecainide—SCN5A—Developmental Biology—NCOR1—hematologic cancer	4.49e-05	0.00117	CbGpPWpGaD
Flecainide—Vision blurred—Methotrexate—hematologic cancer	4.49e-05	0.000113	CcSEcCtD
Flecainide—Rash—Cisplatin—hematologic cancer	4.47e-05	0.000113	CcSEcCtD
Flecainide—Dermatitis—Cisplatin—hematologic cancer	4.46e-05	0.000113	CcSEcCtD
Flecainide—SCN5A—Axon guidance—CREB1—hematologic cancer	4.45e-05	0.00116	CbGpPWpGaD
Flecainide—Diarrhoea—Etoposide—hematologic cancer	4.44e-05	0.000112	CcSEcCtD
Flecainide—Anorexia—Prednisone—hematologic cancer	4.43e-05	0.000112	CcSEcCtD
Flecainide—Eye disorder—Doxorubicin—hematologic cancer	4.43e-05	0.000112	CcSEcCtD
Flecainide—Ill-defined disorder—Methotrexate—hematologic cancer	4.42e-05	0.000112	CcSEcCtD
Flecainide—Tinnitus—Doxorubicin—hematologic cancer	4.42e-05	0.000112	CcSEcCtD
Flecainide—Feeling abnormal—Dexamethasone—hematologic cancer	4.4e-05	0.000111	CcSEcCtD
Flecainide—Feeling abnormal—Betamethasone—hematologic cancer	4.4e-05	0.000111	CcSEcCtD
Flecainide—Flushing—Doxorubicin—hematologic cancer	4.4e-05	0.000111	CcSEcCtD
Flecainide—Flatulence—Epirubicin—hematologic cancer	4.39e-05	0.000111	CcSEcCtD
Flecainide—SCN5A—Developmental Biology—FOXO1—hematologic cancer	4.38e-05	0.00114	CbGpPWpGaD
Flecainide—Tension—Epirubicin—hematologic cancer	4.37e-05	0.00011	CcSEcCtD
Flecainide—Gastrointestinal pain—Betamethasone—hematologic cancer	4.37e-05	0.00011	CcSEcCtD
Flecainide—Gastrointestinal pain—Dexamethasone—hematologic cancer	4.37e-05	0.00011	CcSEcCtD
Flecainide—Dysgeusia—Epirubicin—hematologic cancer	4.36e-05	0.00011	CcSEcCtD
Flecainide—SCN4A—Developmental Biology—MAP2K1—hematologic cancer	4.35e-05	0.00113	CbGpPWpGaD
Flecainide—SCN5A—Axon guidance—IL6R—hematologic cancer	4.34e-05	0.00113	CbGpPWpGaD
Flecainide—Nervousness—Epirubicin—hematologic cancer	4.33e-05	0.000109	CcSEcCtD
Flecainide—SCN5A—SIDS Susceptibility Pathways—TNF—hematologic cancer	4.3e-05	0.00112	CbGpPWpGaD
Flecainide—Malaise—Methotrexate—hematologic cancer	4.29e-05	0.000108	CcSEcCtD
Flecainide—Dizziness—Etoposide—hematologic cancer	4.29e-05	0.000108	CcSEcCtD
Flecainide—SCN5A—Developmental Biology—JAK1—hematologic cancer	4.28e-05	0.00111	CbGpPWpGaD
Flecainide—Immune system disorder—Doxorubicin—hematologic cancer	4.28e-05	0.000108	CcSEcCtD
Flecainide—Vertigo—Methotrexate—hematologic cancer	4.28e-05	0.000108	CcSEcCtD
Flecainide—Leukopenia—Methotrexate—hematologic cancer	4.26e-05	0.000108	CcSEcCtD
Flecainide—Urticaria—Dexamethasone—hematologic cancer	4.24e-05	0.000107	CcSEcCtD
Flecainide—Urticaria—Betamethasone—hematologic cancer	4.24e-05	0.000107	CcSEcCtD
Flecainide—Musculoskeletal discomfort—Prednisone—hematologic cancer	4.24e-05	0.000107	CcSEcCtD
Flecainide—Dizziness—Prednisolone—hematologic cancer	4.23e-05	0.000107	CcSEcCtD
Flecainide—SCN4A—Axon guidance—SRC—hematologic cancer	4.23e-05	0.0011	CbGpPWpGaD
Flecainide—Asthenia—Triamcinolone—hematologic cancer	4.22e-05	0.000107	CcSEcCtD
Flecainide—Abdominal pain—Dexamethasone—hematologic cancer	4.22e-05	0.000107	CcSEcCtD
Flecainide—Body temperature increased—Betamethasone—hematologic cancer	4.22e-05	0.000107	CcSEcCtD
Flecainide—Abdominal pain—Betamethasone—hematologic cancer	4.22e-05	0.000107	CcSEcCtD
Flecainide—Body temperature increased—Dexamethasone—hematologic cancer	4.22e-05	0.000107	CcSEcCtD
Flecainide—Nausea—Cisplatin—hematologic cancer	4.21e-05	0.000106	CcSEcCtD
Flecainide—Insomnia—Prednisone—hematologic cancer	4.21e-05	0.000106	CcSEcCtD
Flecainide—Vision blurred—Epirubicin—hematologic cancer	4.2e-05	0.000106	CcSEcCtD
Flecainide—Alopecia—Doxorubicin—hematologic cancer	4.19e-05	0.000106	CcSEcCtD
Flecainide—Paraesthesia—Prednisone—hematologic cancer	4.18e-05	0.000105	CcSEcCtD
Flecainide—Pruritus—Triamcinolone—hematologic cancer	4.16e-05	0.000105	CcSEcCtD
Flecainide—Cough—Methotrexate—hematologic cancer	4.16e-05	0.000105	CcSEcCtD
Flecainide—SCN4A—Developmental Biology—FGF2—hematologic cancer	4.14e-05	0.00108	CbGpPWpGaD
Flecainide—Ill-defined disorder—Epirubicin—hematologic cancer	4.14e-05	0.000104	CcSEcCtD
Flecainide—SCN5A—Axon guidance—MAP2K1—hematologic cancer	4.13e-05	0.00107	CbGpPWpGaD
Flecainide—Convulsion—Methotrexate—hematologic cancer	4.13e-05	0.000104	CcSEcCtD
Flecainide—Vomiting—Etoposide—hematologic cancer	4.13e-05	0.000104	CcSEcCtD
Flecainide—SCN4A—Axon guidance—VEGFA—hematologic cancer	4.12e-05	0.00107	CbGpPWpGaD
Flecainide—Dyspepsia—Prednisone—hematologic cancer	4.09e-05	0.000103	CcSEcCtD
Flecainide—Rash—Etoposide—hematologic cancer	4.09e-05	0.000103	CcSEcCtD
Flecainide—Dermatitis—Etoposide—hematologic cancer	4.09e-05	0.000103	CcSEcCtD
Flecainide—SCN4A—Axon guidance—NRAS—hematologic cancer	4.07e-05	0.00106	CbGpPWpGaD
Flecainide—Headache—Etoposide—hematologic cancer	4.07e-05	0.000103	CcSEcCtD
Flecainide—Flatulence—Doxorubicin—hematologic cancer	4.06e-05	0.000103	CcSEcCtD
Flecainide—Arthralgia—Methotrexate—hematologic cancer	4.05e-05	0.000102	CcSEcCtD
Flecainide—Chest pain—Methotrexate—hematologic cancer	4.05e-05	0.000102	CcSEcCtD
Flecainide—Myalgia—Methotrexate—hematologic cancer	4.05e-05	0.000102	CcSEcCtD
Flecainide—Tension—Doxorubicin—hematologic cancer	4.05e-05	0.000102	CcSEcCtD
Flecainide—Decreased appetite—Prednisone—hematologic cancer	4.04e-05	0.000102	CcSEcCtD
Flecainide—Dysgeusia—Doxorubicin—hematologic cancer	4.04e-05	0.000102	CcSEcCtD
Flecainide—Rash—Prednisolone—hematologic cancer	4.04e-05	0.000102	CcSEcCtD
Flecainide—Dermatitis—Prednisolone—hematologic cancer	4.03e-05	0.000102	CcSEcCtD
Flecainide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	4.03e-05	0.000102	CcSEcCtD
Flecainide—Malaise—Epirubicin—hematologic cancer	4.02e-05	0.000102	CcSEcCtD
Flecainide—Fatigue—Prednisone—hematologic cancer	4.01e-05	0.000101	CcSEcCtD
Flecainide—Headache—Prednisolone—hematologic cancer	4.01e-05	0.000101	CcSEcCtD
Flecainide—Discomfort—Methotrexate—hematologic cancer	4.01e-05	0.000101	CcSEcCtD
Flecainide—Nervousness—Doxorubicin—hematologic cancer	4.01e-05	0.000101	CcSEcCtD
Flecainide—Vertigo—Epirubicin—hematologic cancer	4e-05	0.000101	CcSEcCtD
Flecainide—Syncope—Epirubicin—hematologic cancer	4e-05	0.000101	CcSEcCtD
Flecainide—Leukopenia—Epirubicin—hematologic cancer	3.99e-05	0.000101	CcSEcCtD
Flecainide—Constipation—Prednisone—hematologic cancer	3.98e-05	0.0001	CcSEcCtD
Flecainide—SCN4A—Developmental Biology—JAK2—hematologic cancer	3.97e-05	0.00103	CbGpPWpGaD
Flecainide—Palpitations—Epirubicin—hematologic cancer	3.94e-05	9.95e-05	CcSEcCtD
Flecainide—Confusional state—Methotrexate—hematologic cancer	3.92e-05	9.9e-05	CcSEcCtD
Flecainide—Loss of consciousness—Epirubicin—hematologic cancer	3.92e-05	9.9e-05	CcSEcCtD
Flecainide—SCN4A—Axon guidance—MAPK3—hematologic cancer	3.9e-05	0.00101	CbGpPWpGaD
Flecainide—Dizziness—Triamcinolone—hematologic cancer	3.89e-05	9.83e-05	CcSEcCtD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—GBA—hematologic cancer	3.89e-05	0.00101	CbGpPWpGaD
Flecainide—Cough—Epirubicin—hematologic cancer	3.89e-05	9.82e-05	CcSEcCtD
Flecainide—Vision blurred—Doxorubicin—hematologic cancer	3.89e-05	9.82e-05	CcSEcCtD
Flecainide—Convulsion—Epirubicin—hematologic cancer	3.86e-05	9.75e-05	CcSEcCtD
Flecainide—Nausea—Etoposide—hematologic cancer	3.85e-05	9.74e-05	CcSEcCtD
Flecainide—Hypertension—Epirubicin—hematologic cancer	3.85e-05	9.72e-05	CcSEcCtD
Flecainide—Feeling abnormal—Prednisone—hematologic cancer	3.83e-05	9.68e-05	CcSEcCtD
Flecainide—Asthenia—Betamethasone—hematologic cancer	3.83e-05	9.68e-05	CcSEcCtD
Flecainide—Asthenia—Dexamethasone—hematologic cancer	3.83e-05	9.68e-05	CcSEcCtD
Flecainide—Ill-defined disorder—Doxorubicin—hematologic cancer	3.83e-05	9.67e-05	CcSEcCtD
Flecainide—Nervous system disorder—Methotrexate—hematologic cancer	3.81e-05	9.63e-05	CcSEcCtD
Flecainide—Thrombocytopenia—Methotrexate—hematologic cancer	3.81e-05	9.61e-05	CcSEcCtD
Flecainide—Gastrointestinal pain—Prednisone—hematologic cancer	3.8e-05	9.61e-05	CcSEcCtD
Flecainide—Nausea—Prednisolone—hematologic cancer	3.8e-05	9.6e-05	CcSEcCtD
Flecainide—Myalgia—Epirubicin—hematologic cancer	3.79e-05	9.59e-05	CcSEcCtD
Flecainide—Chest pain—Epirubicin—hematologic cancer	3.79e-05	9.59e-05	CcSEcCtD
Flecainide—Arthralgia—Epirubicin—hematologic cancer	3.79e-05	9.59e-05	CcSEcCtD
Flecainide—Anxiety—Epirubicin—hematologic cancer	3.78e-05	9.55e-05	CcSEcCtD
Flecainide—Pruritus—Dexamethasone—hematologic cancer	3.78e-05	9.54e-05	CcSEcCtD
Flecainide—Pruritus—Betamethasone—hematologic cancer	3.78e-05	9.54e-05	CcSEcCtD
Flecainide—Skin disorder—Methotrexate—hematologic cancer	3.78e-05	9.54e-05	CcSEcCtD
Flecainide—SCN5A—Axon guidance—JAK2—hematologic cancer	3.77e-05	0.00098	CbGpPWpGaD
Flecainide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	3.77e-05	9.52e-05	CcSEcCtD
Flecainide—Hyperhidrosis—Methotrexate—hematologic cancer	3.76e-05	9.49e-05	CcSEcCtD
Flecainide—Discomfort—Epirubicin—hematologic cancer	3.75e-05	9.47e-05	CcSEcCtD
Flecainide—Vomiting—Triamcinolone—hematologic cancer	3.74e-05	9.45e-05	CcSEcCtD
Flecainide—Malaise—Doxorubicin—hematologic cancer	3.72e-05	9.39e-05	CcSEcCtD
Flecainide—Rash—Triamcinolone—hematologic cancer	3.71e-05	9.37e-05	CcSEcCtD
Flecainide—Dry mouth—Epirubicin—hematologic cancer	3.71e-05	9.37e-05	CcSEcCtD
Flecainide—Dermatitis—Triamcinolone—hematologic cancer	3.71e-05	9.37e-05	CcSEcCtD
Flecainide—Vertigo—Doxorubicin—hematologic cancer	3.7e-05	9.36e-05	CcSEcCtD
Flecainide—Anorexia—Methotrexate—hematologic cancer	3.7e-05	9.36e-05	CcSEcCtD
Flecainide—Syncope—Doxorubicin—hematologic cancer	3.7e-05	9.34e-05	CcSEcCtD
Flecainide—Urticaria—Prednisone—hematologic cancer	3.69e-05	9.33e-05	CcSEcCtD
Flecainide—Leukopenia—Doxorubicin—hematologic cancer	3.69e-05	9.32e-05	CcSEcCtD
Flecainide—Headache—Triamcinolone—hematologic cancer	3.69e-05	9.31e-05	CcSEcCtD
Flecainide—Abdominal pain—Prednisone—hematologic cancer	3.68e-05	9.29e-05	CcSEcCtD
Flecainide—Body temperature increased—Prednisone—hematologic cancer	3.68e-05	9.29e-05	CcSEcCtD
Flecainide—Confusional state—Epirubicin—hematologic cancer	3.67e-05	9.26e-05	CcSEcCtD
Flecainide—Diarrhoea—Betamethasone—hematologic cancer	3.65e-05	9.23e-05	CcSEcCtD
Flecainide—Diarrhoea—Dexamethasone—hematologic cancer	3.65e-05	9.23e-05	CcSEcCtD
Flecainide—Palpitations—Doxorubicin—hematologic cancer	3.64e-05	9.21e-05	CcSEcCtD
Flecainide—Oedema—Epirubicin—hematologic cancer	3.64e-05	9.19e-05	CcSEcCtD
Flecainide—Hypotension—Methotrexate—hematologic cancer	3.63e-05	9.17e-05	CcSEcCtD
Flecainide—Loss of consciousness—Doxorubicin—hematologic cancer	3.62e-05	9.16e-05	CcSEcCtD
Flecainide—Cough—Doxorubicin—hematologic cancer	3.6e-05	9.09e-05	CcSEcCtD
Flecainide—SCN5A—Developmental Biology—MAPK14—hematologic cancer	3.6e-05	0.000934	CbGpPWpGaD
Flecainide—Shock—Epirubicin—hematologic cancer	3.58e-05	9.04e-05	CcSEcCtD
Flecainide—Convulsion—Doxorubicin—hematologic cancer	3.57e-05	9.03e-05	CcSEcCtD
Flecainide—Nervous system disorder—Epirubicin—hematologic cancer	3.57e-05	9.01e-05	CcSEcCtD
Flecainide—Thrombocytopenia—Epirubicin—hematologic cancer	3.56e-05	9e-05	CcSEcCtD
Flecainide—Hypertension—Doxorubicin—hematologic cancer	3.56e-05	8.99e-05	CcSEcCtD
Flecainide—Tachycardia—Epirubicin—hematologic cancer	3.55e-05	8.97e-05	CcSEcCtD
Flecainide—SCN5A—Developmental Biology—MET—hematologic cancer	3.54e-05	0.000921	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—CDK4—hematologic cancer	3.54e-05	0.000921	CbGpPWpGaD
Flecainide—Musculoskeletal discomfort—Methotrexate—hematologic cancer	3.54e-05	8.95e-05	CcSEcCtD
Flecainide—CYP2D6—Biological oxidations—GSTP1—hematologic cancer	3.54e-05	0.00092	CbGpPWpGaD
Flecainide—Skin disorder—Epirubicin—hematologic cancer	3.53e-05	8.93e-05	CcSEcCtD
Flecainide—Dizziness—Betamethasone—hematologic cancer	3.53e-05	8.92e-05	CcSEcCtD
Flecainide—Dizziness—Dexamethasone—hematologic cancer	3.53e-05	8.92e-05	CcSEcCtD
Flecainide—Hyperhidrosis—Epirubicin—hematologic cancer	3.52e-05	8.88e-05	CcSEcCtD
Flecainide—Insomnia—Methotrexate—hematologic cancer	3.52e-05	8.88e-05	CcSEcCtD
Flecainide—Arthralgia—Doxorubicin—hematologic cancer	3.51e-05	8.87e-05	CcSEcCtD
Flecainide—Chest pain—Doxorubicin—hematologic cancer	3.51e-05	8.87e-05	CcSEcCtD
Flecainide—Myalgia—Doxorubicin—hematologic cancer	3.51e-05	8.87e-05	CcSEcCtD
Flecainide—CYP2C9—Biological oxidations—GSTP1—hematologic cancer	3.51e-05	0.000912	CbGpPWpGaD
Flecainide—SCN4A—Axon guidance—KRAS—hematologic cancer	3.5e-05	0.000911	CbGpPWpGaD
Flecainide—Anxiety—Doxorubicin—hematologic cancer	3.5e-05	8.84e-05	CcSEcCtD
Flecainide—Nausea—Triamcinolone—hematologic cancer	3.5e-05	8.83e-05	CcSEcCtD
Flecainide—Paraesthesia—Methotrexate—hematologic cancer	3.49e-05	8.82e-05	CcSEcCtD
Flecainide—CYP2D6—Metapathway biotransformation—GSTP1—hematologic cancer	3.49e-05	0.000907	CbGpPWpGaD
Flecainide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	3.49e-05	8.81e-05	CcSEcCtD
Flecainide—Discomfort—Doxorubicin—hematologic cancer	3.47e-05	8.76e-05	CcSEcCtD
Flecainide—SCN5A—SIDS Susceptibility Pathways—IL6—hematologic cancer	3.47e-05	0.000901	CbGpPWpGaD
Flecainide—Anorexia—Epirubicin—hematologic cancer	3.47e-05	8.76e-05	CcSEcCtD
Flecainide—Dyspnoea—Methotrexate—hematologic cancer	3.47e-05	8.75e-05	CcSEcCtD
Flecainide—CYP2C9—Metapathway biotransformation—GSTP1—hematologic cancer	3.46e-05	0.000899	CbGpPWpGaD
Flecainide—Somnolence—Methotrexate—hematologic cancer	3.46e-05	8.73e-05	CcSEcCtD
Flecainide—Dry mouth—Doxorubicin—hematologic cancer	3.43e-05	8.67e-05	CcSEcCtD
Flecainide—Dyspepsia—Methotrexate—hematologic cancer	3.42e-05	8.64e-05	CcSEcCtD
Flecainide—SCN5A—Developmental Biology—NOTCH1—hematologic cancer	3.41e-05	0.000886	CbGpPWpGaD
Flecainide—Hypotension—Epirubicin—hematologic cancer	3.4e-05	8.59e-05	CcSEcCtD
Flecainide—Vomiting—Dexamethasone—hematologic cancer	3.4e-05	8.58e-05	CcSEcCtD
Flecainide—Vomiting—Betamethasone—hematologic cancer	3.4e-05	8.58e-05	CcSEcCtD
Flecainide—Confusional state—Doxorubicin—hematologic cancer	3.39e-05	8.57e-05	CcSEcCtD
Flecainide—Decreased appetite—Methotrexate—hematologic cancer	3.38e-05	8.54e-05	CcSEcCtD
Flecainide—Rash—Betamethasone—hematologic cancer	3.37e-05	8.51e-05	CcSEcCtD
Flecainide—Rash—Dexamethasone—hematologic cancer	3.37e-05	8.51e-05	CcSEcCtD
Flecainide—Oedema—Doxorubicin—hematologic cancer	3.37e-05	8.5e-05	CcSEcCtD
Flecainide—Dermatitis—Betamethasone—hematologic cancer	3.36e-05	8.5e-05	CcSEcCtD
Flecainide—Dermatitis—Dexamethasone—hematologic cancer	3.36e-05	8.5e-05	CcSEcCtD
Flecainide—Gastrointestinal disorder—Methotrexate—hematologic cancer	3.36e-05	8.48e-05	CcSEcCtD
Flecainide—Fatigue—Methotrexate—hematologic cancer	3.35e-05	8.47e-05	CcSEcCtD
Flecainide—Headache—Dexamethasone—hematologic cancer	3.35e-05	8.45e-05	CcSEcCtD
Flecainide—Headache—Betamethasone—hematologic cancer	3.35e-05	8.45e-05	CcSEcCtD
Flecainide—Asthenia—Prednisone—hematologic cancer	3.34e-05	8.43e-05	CcSEcCtD
Flecainide—Pain—Methotrexate—hematologic cancer	3.32e-05	8.4e-05	CcSEcCtD
Flecainide—Musculoskeletal discomfort—Epirubicin—hematologic cancer	3.31e-05	8.37e-05	CcSEcCtD
Flecainide—Shock—Doxorubicin—hematologic cancer	3.31e-05	8.36e-05	CcSEcCtD
Flecainide—Nervous system disorder—Doxorubicin—hematologic cancer	3.3e-05	8.34e-05	CcSEcCtD
Flecainide—Thrombocytopenia—Doxorubicin—hematologic cancer	3.3e-05	8.32e-05	CcSEcCtD
Flecainide—Pruritus—Prednisone—hematologic cancer	3.29e-05	8.31e-05	CcSEcCtD
Flecainide—Insomnia—Epirubicin—hematologic cancer	3.29e-05	8.31e-05	CcSEcCtD
Flecainide—Tachycardia—Doxorubicin—hematologic cancer	3.28e-05	8.3e-05	CcSEcCtD
Flecainide—SCN5A—Developmental Biology—PTPN11—hematologic cancer	3.28e-05	0.000851	CbGpPWpGaD
Flecainide—Skin disorder—Doxorubicin—hematologic cancer	3.27e-05	8.26e-05	CcSEcCtD
Flecainide—Paraesthesia—Epirubicin—hematologic cancer	3.27e-05	8.25e-05	CcSEcCtD
Flecainide—Hyperhidrosis—Doxorubicin—hematologic cancer	3.25e-05	8.22e-05	CcSEcCtD
Flecainide—CYP2D6—Biological oxidations—GSTM1—hematologic cancer	3.25e-05	0.000845	CbGpPWpGaD
Flecainide—Dyspnoea—Epirubicin—hematologic cancer	3.24e-05	8.19e-05	CcSEcCtD
Flecainide—Somnolence—Epirubicin—hematologic cancer	3.23e-05	8.17e-05	CcSEcCtD
Flecainide—CYP2C9—Biological oxidations—GSTM1—hematologic cancer	3.22e-05	0.000838	CbGpPWpGaD
Flecainide—Anorexia—Doxorubicin—hematologic cancer	3.21e-05	8.1e-05	CcSEcCtD
Flecainide—CYP2D6—Metapathway biotransformation—GSTM1—hematologic cancer	3.21e-05	0.000834	CbGpPWpGaD
Flecainide—Feeling abnormal—Methotrexate—hematologic cancer	3.2e-05	8.09e-05	CcSEcCtD
Flecainide—Dyspepsia—Epirubicin—hematologic cancer	3.2e-05	8.09e-05	CcSEcCtD
Flecainide—Diarrhoea—Prednisone—hematologic cancer	3.18e-05	8.04e-05	CcSEcCtD
Flecainide—CYP2C9—Metapathway biotransformation—GSTM1—hematologic cancer	3.18e-05	0.000826	CbGpPWpGaD
Flecainide—Gastrointestinal pain—Methotrexate—hematologic cancer	3.18e-05	8.03e-05	CcSEcCtD
Flecainide—SCN5A—Developmental Biology—CREB1—hematologic cancer	3.17e-05	0.000825	CbGpPWpGaD
Flecainide—Nausea—Dexamethasone—hematologic cancer	3.17e-05	8.01e-05	CcSEcCtD
Flecainide—Nausea—Betamethasone—hematologic cancer	3.17e-05	8.01e-05	CcSEcCtD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—FHL2—hematologic cancer	3.17e-05	0.000824	CbGpPWpGaD
Flecainide—Decreased appetite—Epirubicin—hematologic cancer	3.16e-05	7.99e-05	CcSEcCtD
Flecainide—Hypotension—Doxorubicin—hematologic cancer	3.14e-05	7.94e-05	CcSEcCtD
Flecainide—Gastrointestinal disorder—Epirubicin—hematologic cancer	3.14e-05	7.93e-05	CcSEcCtD
Flecainide—Fatigue—Epirubicin—hematologic cancer	3.14e-05	7.92e-05	CcSEcCtD
Flecainide—Constipation—Epirubicin—hematologic cancer	3.11e-05	7.86e-05	CcSEcCtD
Flecainide—Pain—Epirubicin—hematologic cancer	3.11e-05	7.86e-05	CcSEcCtD
Flecainide—SCN4A—Developmental Biology—EP300—hematologic cancer	3.11e-05	0.000807	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—IL6R—hematologic cancer	3.1e-05	0.000805	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—CREBBP—hematologic cancer	3.09e-05	0.000803	CbGpPWpGaD
Flecainide—Urticaria—Methotrexate—hematologic cancer	3.09e-05	7.8e-05	CcSEcCtD
Flecainide—Dizziness—Prednisone—hematologic cancer	3.08e-05	7.77e-05	CcSEcCtD
Flecainide—Abdominal pain—Methotrexate—hematologic cancer	3.07e-05	7.76e-05	CcSEcCtD
Flecainide—Body temperature increased—Methotrexate—hematologic cancer	3.07e-05	7.76e-05	CcSEcCtD
Flecainide—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	3.07e-05	7.75e-05	CcSEcCtD
Flecainide—Insomnia—Doxorubicin—hematologic cancer	3.04e-05	7.69e-05	CcSEcCtD
Flecainide—Paraesthesia—Doxorubicin—hematologic cancer	3.02e-05	7.63e-05	CcSEcCtD
Flecainide—SCN4A—Developmental Biology—SRC—hematologic cancer	3.02e-05	0.000785	CbGpPWpGaD
Flecainide—Dyspnoea—Doxorubicin—hematologic cancer	3e-05	7.58e-05	CcSEcCtD
Flecainide—Feeling abnormal—Epirubicin—hematologic cancer	3e-05	7.57e-05	CcSEcCtD
Flecainide—Somnolence—Doxorubicin—hematologic cancer	2.99e-05	7.56e-05	CcSEcCtD
Flecainide—SCN4A—Axon guidance—HRAS—hematologic cancer	2.98e-05	0.000774	CbGpPWpGaD
Flecainide—Gastrointestinal pain—Epirubicin—hematologic cancer	2.97e-05	7.51e-05	CcSEcCtD
Flecainide—Dyspepsia—Doxorubicin—hematologic cancer	2.96e-05	7.48e-05	CcSEcCtD
Flecainide—Vomiting—Prednisone—hematologic cancer	2.96e-05	7.47e-05	CcSEcCtD
Flecainide—SCN5A—Developmental Biology—MAP2K1—hematologic cancer	2.95e-05	0.000767	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—VEGFA—hematologic cancer	2.94e-05	0.000764	CbGpPWpGaD
Flecainide—Rash—Prednisone—hematologic cancer	2.93e-05	7.41e-05	CcSEcCtD
Flecainide—Dermatitis—Prednisone—hematologic cancer	2.93e-05	7.4e-05	CcSEcCtD
Flecainide—Decreased appetite—Doxorubicin—hematologic cancer	2.93e-05	7.39e-05	CcSEcCtD
Flecainide—Headache—Prednisone—hematologic cancer	2.91e-05	7.36e-05	CcSEcCtD
Flecainide—SCN4A—Developmental Biology—STAT3—hematologic cancer	2.91e-05	0.000757	CbGpPWpGaD
Flecainide—Gastrointestinal disorder—Doxorubicin—hematologic cancer	2.91e-05	7.34e-05	CcSEcCtD
Flecainide—SCN4A—Developmental Biology—NRAS—hematologic cancer	2.9e-05	0.000755	CbGpPWpGaD
Flecainide—Fatigue—Doxorubicin—hematologic cancer	2.9e-05	7.33e-05	CcSEcCtD
Flecainide—Urticaria—Epirubicin—hematologic cancer	2.89e-05	7.3e-05	CcSEcCtD
Flecainide—Pain—Doxorubicin—hematologic cancer	2.88e-05	7.27e-05	CcSEcCtD
Flecainide—Constipation—Doxorubicin—hematologic cancer	2.88e-05	7.27e-05	CcSEcCtD
Flecainide—Abdominal pain—Epirubicin—hematologic cancer	2.88e-05	7.26e-05	CcSEcCtD
Flecainide—Body temperature increased—Epirubicin—hematologic cancer	2.88e-05	7.26e-05	CcSEcCtD
Flecainide—SCN5A—Axon guidance—SRC—hematologic cancer	2.87e-05	0.000746	CbGpPWpGaD
Flecainide—SCN4A—Axon guidance—IL6—hematologic cancer	2.85e-05	0.000741	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—FGF2—hematologic cancer	2.81e-05	0.000729	CbGpPWpGaD
Flecainide—SCN5A—Axon guidance—VEGFA—hematologic cancer	2.79e-05	0.000726	CbGpPWpGaD
Flecainide—Asthenia—Methotrexate—hematologic cancer	2.79e-05	7.04e-05	CcSEcCtD
Flecainide—SCN4A—Developmental Biology—MAPK3—hematologic cancer	2.78e-05	0.000723	CbGpPWpGaD
Flecainide—Feeling abnormal—Doxorubicin—hematologic cancer	2.77e-05	7.01e-05	CcSEcCtD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—ARNTL—hematologic cancer	2.77e-05	0.00072	CbGpPWpGaD
Flecainide—Nausea—Prednisone—hematologic cancer	2.76e-05	6.98e-05	CcSEcCtD
Flecainide—SCN5A—Axon guidance—NRAS—hematologic cancer	2.76e-05	0.000717	CbGpPWpGaD
Flecainide—Gastrointestinal pain—Doxorubicin—hematologic cancer	2.75e-05	6.95e-05	CcSEcCtD
Flecainide—Pruritus—Methotrexate—hematologic cancer	2.75e-05	6.95e-05	CcSEcCtD
Flecainide—CYP2D6—Metabolism—FTCD—hematologic cancer	2.71e-05	0.000705	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—GMPS—hematologic cancer	2.71e-05	0.000705	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—PHYH—hematologic cancer	2.71e-05	0.000705	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—TGFB1—hematologic cancer	2.7e-05	0.000702	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—JAK2—hematologic cancer	2.69e-05	0.000699	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—FTCD—hematologic cancer	2.69e-05	0.000699	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—GMPS—hematologic cancer	2.69e-05	0.000699	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—PHYH—hematologic cancer	2.69e-05	0.000699	CbGpPWpGaD
Flecainide—Urticaria—Doxorubicin—hematologic cancer	2.67e-05	6.75e-05	CcSEcCtD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—NCOR2—hematologic cancer	2.66e-05	0.000692	CbGpPWpGaD
Flecainide—Body temperature increased—Doxorubicin—hematologic cancer	2.66e-05	6.72e-05	CcSEcCtD
Flecainide—Abdominal pain—Doxorubicin—hematologic cancer	2.66e-05	6.72e-05	CcSEcCtD
Flecainide—Diarrhoea—Methotrexate—hematologic cancer	2.66e-05	6.72e-05	CcSEcCtD
Flecainide—SCN5A—Axon guidance—MAPK3—hematologic cancer	2.64e-05	0.000687	CbGpPWpGaD
Flecainide—Asthenia—Epirubicin—hematologic cancer	2.61e-05	6.59e-05	CcSEcCtD
Flecainide—Pruritus—Epirubicin—hematologic cancer	2.57e-05	6.5e-05	CcSEcCtD
Flecainide—Dizziness—Methotrexate—hematologic cancer	2.57e-05	6.49e-05	CcSEcCtD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—IDH1—hematologic cancer	2.53e-05	0.000659	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—TNF—hematologic cancer	2.52e-05	0.000655	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—ABCC3—hematologic cancer	2.51e-05	0.000651	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—KRAS—hematologic cancer	2.5e-05	0.00065	CbGpPWpGaD
Flecainide—Diarrhoea—Epirubicin—hematologic cancer	2.49e-05	6.29e-05	CcSEcCtD
Flecainide—CYP2D6—Metabolism—SMPD3—hematologic cancer	2.48e-05	0.000645	CbGpPWpGaD
Flecainide—Vomiting—Methotrexate—hematologic cancer	2.47e-05	6.24e-05	CcSEcCtD
Flecainide—CYP2C9—Metabolism—SMPD3—hematologic cancer	2.46e-05	0.000639	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—SPHK1—hematologic cancer	2.45e-05	0.000638	CbGpPWpGaD
Flecainide—Rash—Methotrexate—hematologic cancer	2.45e-05	6.19e-05	CcSEcCtD
Flecainide—Dermatitis—Methotrexate—hematologic cancer	2.45e-05	6.19e-05	CcSEcCtD
Flecainide—Headache—Methotrexate—hematologic cancer	2.43e-05	6.15e-05	CcSEcCtD
Flecainide—Asthenia—Doxorubicin—hematologic cancer	2.41e-05	6.1e-05	CcSEcCtD
Flecainide—Dizziness—Epirubicin—hematologic cancer	2.41e-05	6.08e-05	CcSEcCtD
Flecainide—Pruritus—Doxorubicin—hematologic cancer	2.38e-05	6.02e-05	CcSEcCtD
Flecainide—SCN5A—Axon guidance—KRAS—hematologic cancer	2.38e-05	0.000617	CbGpPWpGaD
Flecainide—Vomiting—Epirubicin—hematologic cancer	2.31e-05	5.84e-05	CcSEcCtD
Flecainide—Nausea—Methotrexate—hematologic cancer	2.31e-05	5.83e-05	CcSEcCtD
Flecainide—Diarrhoea—Doxorubicin—hematologic cancer	2.3e-05	5.82e-05	CcSEcCtD
Flecainide—Rash—Epirubicin—hematologic cancer	2.29e-05	5.79e-05	CcSEcCtD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—hematologic cancer	2.29e-05	0.000596	CbGpPWpGaD
Flecainide—Dermatitis—Epirubicin—hematologic cancer	2.29e-05	5.79e-05	CcSEcCtD
Flecainide—Headache—Epirubicin—hematologic cancer	2.28e-05	5.76e-05	CcSEcCtD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—ALOX5—hematologic cancer	2.23e-05	0.000581	CbGpPWpGaD
Flecainide—Dizziness—Doxorubicin—hematologic cancer	2.23e-05	5.62e-05	CcSEcCtD
Flecainide—CYP2D6—Metabolism—B3GAT1—hematologic cancer	2.17e-05	0.000563	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—DCK—hematologic cancer	2.17e-05	0.000563	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—ASNS—hematologic cancer	2.17e-05	0.000563	CbGpPWpGaD
Flecainide—Nausea—Epirubicin—hematologic cancer	2.16e-05	5.46e-05	CcSEcCtD
Flecainide—CYP2C9—Metabolism—DCK—hematologic cancer	2.15e-05	0.000559	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—B3GAT1—hematologic cancer	2.15e-05	0.000559	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—ASNS—hematologic cancer	2.15e-05	0.000559	CbGpPWpGaD
Flecainide—Vomiting—Doxorubicin—hematologic cancer	2.14e-05	5.41e-05	CcSEcCtD
Flecainide—SCN4A—Developmental Biology—HRAS—hematologic cancer	2.13e-05	0.000552	CbGpPWpGaD
Flecainide—Rash—Doxorubicin—hematologic cancer	2.12e-05	5.36e-05	CcSEcCtD
Flecainide—Dermatitis—Doxorubicin—hematologic cancer	2.12e-05	5.36e-05	CcSEcCtD
Flecainide—Headache—Doxorubicin—hematologic cancer	2.11e-05	5.33e-05	CcSEcCtD
Flecainide—SCN5A—Developmental Biology—EP300—hematologic cancer	2.11e-05	0.000547	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—NCOA3—hematologic cancer	2.1e-05	0.000546	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—HDC—hematologic cancer	2.05e-05	0.000534	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—SRC—hematologic cancer	2.05e-05	0.000532	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—HDC—hematologic cancer	2.04e-05	0.00053	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—IL6—hematologic cancer	2.03e-05	0.000529	CbGpPWpGaD
Flecainide—SCN5A—Axon guidance—HRAS—hematologic cancer	2.02e-05	0.000525	CbGpPWpGaD
Flecainide—Nausea—Doxorubicin—hematologic cancer	2e-05	5.05e-05	CcSEcCtD
Flecainide—SCN5A—Developmental Biology—VEGFA—hematologic cancer	1.99e-05	0.000518	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—STAT3—hematologic cancer	1.97e-05	0.000513	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—NRAS—hematologic cancer	1.97e-05	0.000512	CbGpPWpGaD
Flecainide—SCN5A—Axon guidance—IL6—hematologic cancer	1.93e-05	0.000502	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—SDC1—hematologic cancer	1.9e-05	0.000494	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—MAPK3—hematologic cancer	1.89e-05	0.00049	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—CDA—hematologic cancer	1.88e-05	0.000489	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—AKT1—hematologic cancer	1.88e-05	0.000488	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—CDA—hematologic cancer	1.86e-05	0.000484	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—TGFB1—hematologic cancer	1.83e-05	0.000476	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—PC—hematologic cancer	1.81e-05	0.00047	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—PC—hematologic cancer	1.79e-05	0.000466	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—GBA—hematologic cancer	1.75e-05	0.000454	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—SLC35B2—hematologic cancer	1.75e-05	0.000454	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—GBA—hematologic cancer	1.73e-05	0.00045	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—SLC35B2—hematologic cancer	1.73e-05	0.00045	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—TNF—hematologic cancer	1.71e-05	0.000444	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—KRAS—hematologic cancer	1.69e-05	0.000441	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—MTAP—hematologic cancer	1.6e-05	0.000415	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—MTAP—hematologic cancer	1.58e-05	0.000412	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—HRAS—hematologic cancer	1.44e-05	0.000374	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—FHL2—hematologic cancer	1.42e-05	0.00037	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—FHL2—hematologic cancer	1.41e-05	0.000367	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—AGRN—hematologic cancer	1.4e-05	0.000363	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—AGRN—hematologic cancer	1.38e-05	0.00036	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—IL6—hematologic cancer	1.38e-05	0.000358	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—HMMR—hematologic cancer	1.32e-05	0.000344	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—IDH2—hematologic cancer	1.32e-05	0.000344	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—IDH2—hematologic cancer	1.31e-05	0.000341	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—HMMR—hematologic cancer	1.31e-05	0.000341	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—AKT1—hematologic cancer	1.27e-05	0.000331	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—ARNTL—hematologic cancer	1.25e-05	0.000324	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—hematologic cancer	1.24e-05	0.000322	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—ARNTL—hematologic cancer	1.23e-05	0.000321	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—ACP5—hematologic cancer	1.21e-05	0.000315	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—CA9—hematologic cancer	1.21e-05	0.000315	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—ACP5—hematologic cancer	1.2e-05	0.000312	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—CA9—hematologic cancer	1.2e-05	0.000312	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—NCOR2—hematologic cancer	1.2e-05	0.000311	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—NCOR2—hematologic cancer	1.19e-05	0.000308	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—IDH1—hematologic cancer	1.14e-05	0.000296	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—IDH1—hematologic cancer	1.13e-05	0.000293	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—GSTO1—hematologic cancer	1.13e-05	0.000293	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—ABCC3—hematologic cancer	1.13e-05	0.000293	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—TXN—hematologic cancer	1.13e-05	0.000293	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—GSTO1—hematologic cancer	1.12e-05	0.00029	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—ABCC3—hematologic cancer	1.12e-05	0.00029	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—TXN—hematologic cancer	1.12e-05	0.00029	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—SPHK1—hematologic cancer	1.1e-05	0.000286	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—SPHK1—hematologic cancer	1.09e-05	0.000284	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—UGT1A1—hematologic cancer	1.06e-05	0.000275	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—UGT1A1—hematologic cancer	1.05e-05	0.000273	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—SLC22A1—hematologic cancer	1.03e-05	0.000268	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—CRABP1—hematologic cancer	1.03e-05	0.000268	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—CRABP1—hematologic cancer	1.02e-05	0.000265	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—SLC22A1—hematologic cancer	1.02e-05	0.000265	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—ALOX5—hematologic cancer	1e-05	0.000261	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—ALOX5—hematologic cancer	9.95e-06	0.000259	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—NUP98—hematologic cancer	9.72e-06	0.000253	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—NUP98—hematologic cancer	9.64e-06	0.00025	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—ADCY7—hematologic cancer	9.44e-06	0.000245	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—NCOA3—hematologic cancer	9.44e-06	0.000245	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—NUP214—hematologic cancer	9.37e-06	0.000244	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—ADCY7—hematologic cancer	9.35e-06	0.000243	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—NCOA3—hematologic cancer	9.35e-06	0.000243	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—NUP214—hematologic cancer	9.29e-06	0.000241	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	9.19e-06	0.000239	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—MTR—hematologic cancer	9.18e-06	0.000239	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—ABCG2—hematologic cancer	9.18e-06	0.000239	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—ABCG2—hematologic cancer	9.1e-06	0.000237	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—MTR—hematologic cancer	9.1e-06	0.000237	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—ENO2—hematologic cancer	9e-06	0.000234	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—ENO2—hematologic cancer	8.92e-06	0.000232	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—GSTT1—hematologic cancer	8.73e-06	0.000227	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—GSTT1—hematologic cancer	8.65e-06	0.000225	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—SDC1—hematologic cancer	8.53e-06	0.000222	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	8.52e-06	0.000222	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—SDC1—hematologic cancer	8.46e-06	0.00022	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	8.08e-06	0.00021	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	7.98e-06	0.000207	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	7.63e-06	0.000198	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—NQO1—hematologic cancer	7.26e-06	0.000189	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—CD44—hematologic cancer	7.26e-06	0.000189	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—NQO1—hematologic cancer	7.19e-06	0.000187	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—CD44—hematologic cancer	7.19e-06	0.000187	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	7.04e-06	0.000183	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—CYCS—hematologic cancer	6.87e-06	0.000178	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—HSP90AA1—hematologic cancer	6.82e-06	0.000177	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—CYCS—hematologic cancer	6.81e-06	0.000177	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—HSP90AA1—hematologic cancer	6.76e-06	0.000176	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	6.09e-06	0.000158	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—GSTP1—hematologic cancer	6.05e-06	0.000157	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—GSTP1—hematologic cancer	6e-06	0.000156	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	5.8e-06	0.000151	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—ABCB1—hematologic cancer	5.73e-06	0.000149	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—ABCB1—hematologic cancer	5.68e-06	0.000148	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—GSTM1—hematologic cancer	5.56e-06	0.000145	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—NCOR1—hematologic cancer	5.56e-06	0.000145	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—NCOR1—hematologic cancer	5.51e-06	0.000143	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—GSTM1—hematologic cancer	5.51e-06	0.000143	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—MTHFR—hematologic cancer	4.91e-06	0.000128	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—MTHFR—hematologic cancer	4.87e-06	0.000127	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	4.29e-06	0.000112	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—PIK3CG—hematologic cancer	4.13e-06	0.000107	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—PIK3CG—hematologic cancer	4.09e-06	0.000106	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—CREBBP—hematologic cancer	3.83e-06	9.95e-05	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—CREBBP—hematologic cancer	3.8e-06	9.86e-05	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—PIK3CD—hematologic cancer	3.63e-06	9.44e-05	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—PIK3CD—hematologic cancer	3.6e-06	9.35e-05	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—ALB—hematologic cancer	3.58e-06	9.31e-05	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—ALB—hematologic cancer	3.55e-06	9.23e-05	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—PIK3R1—hematologic cancer	3.43e-06	8.91e-05	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—PIK3R1—hematologic cancer	3.4e-06	8.83e-05	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—PIK3CB—hematologic cancer	3.16e-06	8.22e-05	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—PIK3CB—hematologic cancer	3.14e-06	8.15e-05	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—PTEN—hematologic cancer	2.73e-06	7.11e-05	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—PTEN—hematologic cancer	2.71e-06	7.04e-05	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—EP300—hematologic cancer	2.61e-06	6.78e-05	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—EP300—hematologic cancer	2.58e-06	6.72e-05	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—PIK3CA—hematologic cancer	1.93e-06	5.01e-05	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—PIK3CA—hematologic cancer	1.91e-06	4.97e-05	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—AKT1—hematologic cancer	1.58e-06	4.1e-05	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—AKT1—hematologic cancer	1.56e-06	4.06e-05	CbGpPWpGaD
